Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD

Rice Hall James & Associates LLC acquired a new stake in iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 30,444 shares of the medical equipment provider’s stock, valued at approximately $2,909,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Global Retirement Partners LLC bought a new stake in iRadimed during the second quarter worth approximately $84,000. Bank of New York Mellon Corp bought a new position in iRadimed during the 2nd quarter valued at $7,252,000. State of Wyoming bought a new position in iRadimed during the 2nd quarter valued at $130,000. GSA Capital Partners LLP acquired a new position in shares of iRadimed during the 2nd quarter valued at $675,000. Finally, Summit Global Investments acquired a new position in shares of iRadimed during the 2nd quarter valued at $354,000. 92.34% of the stock is currently owned by institutional investors.

Insider Buying and Selling at iRadimed

In other news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

IRMD has been the topic of a number of research reports. Wall Street Zen downgraded iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Price Performance

NASDAQ IRMD opened at $87.55 on Wednesday. The company’s 50 day simple moving average is $93.87 and its 200 day simple moving average is $94.70. iRadimed Corporation has a 12 month low of $67.84 and a 12 month high of $107.90. The company has a market capitalization of $1.12 billion, a P/E ratio of 48.91 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts anticipate that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s dividend payout ratio is 44.69%.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.